Abstract 331P
Background
SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has killed over five hundred thousand people and has infected over 13 million people across the world in over 200 countries. Cancer patients fall under the high-risk category and are susceptible to the SARS-CoV-2 infection given the need for frequent hospital visits.
Methods
In this study, I analysed data from 46 cancer patients who were affected with different types of cancers (Table) and continued to receive cytotoxic treatment between January 2020 till July 2020. Table: 331P
Summary of the types of cancer and the treatment regimen of the 46 patients
Type of cancer | Number of patients | Treatment regimen |
Astrocytoma | 1 | Temodal + Bevacizumab |
Breast | 3 | EC + T |
Breast | 8 | EC + TC |
Breast | 4 | EC + THP |
Colorectal cancer | 4 | FOLFOX |
Colorectal cancer | 3 | FOLFIRI |
Colorectal cancer | 1 | FOLFOX + Bevacizumab |
Ewing sarcoma | 1 | VCD/IE |
Gastric cancer | 4 | FLOT |
Gastric cancer | 2 | XELOX |
Lung cancer | 4 | Docetaxel + Carboplatin |
Lung cancer | 1 | Topotecan |
Lung cancer | 4 | Etoposide + Carboplatin |
Lung cancer | 1 | Docetaxel + Cisplatin |
Osteosarcoma | 1 | OS99 |
Osteosarcoma | 1 | HD-MTX |
Pancreatic cancer | 2 | FOLFIRINOX |
Small bowel | 1 | FOLFOX |
Results
All the 46 patients included in the study completed their cytotoxic regimen without developing SARS-CoV-2 infection between January till July 2020.
Conclusions
The results from the study led to the hypothesis that three factors which were common among the cancer patients included in the study namely, 1) the use of granulocyte colony-stimulating factor (G-CSF), 2) the use of dexamethasone and, 3) dysbiosis of microbiome among cancer patients might be potential reasons for evading the deadly SARS-CoV-2 infection, despite their compromised immune status and a high likelihood of repeated exposure during hospital visits in comparison to the healthy general population, who are less likely to visit hospitals during the pandemic. The study aims to provide an alternate perspective and instigate discussion over the continuation of providing cancer care amidst the pandemic.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
153P - Mutational landscape of gastric cancer (GC) in adolescents and young adults (AYA) in Asia from 2015-2019
Presenter: Evelyn Yi Ting Wong
Session: e-Poster Display Session
154P - A multicenter, prospective study of apatinib plus chemotherapy as neoadjuvant treatment for locally advanced gastric cancer
Presenter: Yi-Hui Tang
Session: e-Poster Display Session
155P - Surgical outcomes and technical performance of robotic versus laparoscopic total gastrectomy for gastric cancer: A prospective comparative study FUGES-014
Presenter: Hua-Gen Wang
Session: e-Poster Display Session
156P - Safety and feasibility of laparoscopic spleen-preserving splenic hilar lymphadenectomy during total gastrectomy for advanced proximal gastric cancer: A randomized clinical trial
Presenter: Jian-Xian Lin
Session: e-Poster Display Session
157P - Efficacy and safety of penpulimab (AK105), a new generation anti-programmed cell death-1 (PD-1) antibody, in upper gastrointestinal cancers
Presenter: Amy Prawira
Session: e-Poster Display Session
158P - A phase II study of trastuzumab with S-1 plus oxaliplatin for HER2-positive advanced gastric cancer (HIGHSOX study): Final report
Presenter: Atsuo Takashima
Session: e-Poster Display Session
159P - Open surgery can improve the 3-year postoperative survival in some patients with advanced gastric cancer compared with laparoscopic surgery: A multicenter, propensity score matching, in-depth analysis
Presenter: Ze-Ning Huang
Session: e-Poster Display Session
160P - Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma
Presenter: Ning Li
Session: e-Poster Display Session
161P - Adjuvant tegafur/gimeracil/oteracil (S-1) versus platinum-based chemotherapies for resectable gastric cancer: Real-world experience and a propensity score matching analysis
Presenter: Chih Chieh Yen
Session: e-Poster Display Session
162P - Evaluation of neutrophil/lymphocyte ratio (NLR) in monitoring anastomotic leakage after radical total gastrectomy for gastric cancer
Presenter: Ru-Hong Tu
Session: e-Poster Display Session